Distinct trends were seen in etiology-based mortality with chronic liver disease before, during, and after the COVID-19 pandemic.

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...